Beyond Air (NASDAQ:XAIR – Get Free Report) is anticipated to announce its Q2 2027 results after the market closes on Wednesday, November 11th. Analysts expect Beyond Air to post earnings of ($3.31) per share and revenue of $2.16 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2027 earnings results page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:30 PM ET.
Beyond Air (NASDAQ:XAIR – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($11.00) EPS for the quarter, missing the consensus estimate of ($10.80) by ($0.20). Beyond Air had a negative return on equity of 440.26% and a negative net margin of 435.71%. The company had revenue of $1.77 million during the quarter, compared to analysts’ expectations of $1.93 million.
Beyond Air Price Performance
Shares of NASDAQ XAIR opened at $2.32 on Wednesday. The company’s fifty day moving average price is $2.93 and its 200 day moving average price is $10.39. Beyond Air has a 1 year low of $2.05 and a 1 year high of $53.20. The company has a debt-to-equity ratio of 7.81, a current ratio of 3.31 and a quick ratio of 3.12.
Analysts Set New Price Targets
XAIR has been the subject of a number of research reports. Lake Street Capital initiated coverage on shares of Beyond Air in a research note on Tuesday, September 1st. They set a “buy” rating and a $10.00 target price for the company. Weiss Ratings raised shares of Beyond Air from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, October 29th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $105.00.
Read Our Latest Analysis on Beyond Air
Beyond Air Company Profile
Beyond Air, Inc is a medical technology and biopharmaceutical company focused on developing nitric oxide (NO) therapies and delivery systems for respiratory diseases and other serious medical conditions. Its platform is designed to generate NO from ambient air at the point of care, potentially reducing reliance on traditional high-pressure gas cylinders.
The company’s primary product family is LungFit, a series of compact NO delivery systems intended for use in hospital and clinical settings.
See Also
- Five stocks we like better than Beyond Air
- Shopify’s Small Q3 Miss Triggered a Big Sell-Off: What’s Next?
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
Receive News & Ratings for Beyond Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyond Air and related companies with MarketBeat.com's FREE daily email newsletter.
